Imperva Inc (NYSE:IMPV)‘s stock had its “overweight” rating restated by Stephens in a research note issued on Thursday. They presently have a $61.00 price objective on the software maker’s stock, up from their prior price objective of $53.00. Stephens’ target price suggests a potential upside of 19.96% from the stock’s current price.

Several other research analysts also recently issued reports on the company. ValuEngine downgraded Imperva from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. BidaskClub downgraded Imperva from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 5th. Susquehanna Bancshares Inc began coverage on Imperva in a research note on Wednesday, June 7th. They issued a “positive” rating and a $60.00 price objective for the company. UBS AG began coverage on Imperva in a research note on Tuesday, June 6th. They issued a “positive” rating and a $60.00 price objective for the company. Finally, Evercore ISI reaffirmed a “buy” rating and issued a $56.00 price objective on shares of Imperva in a research note on Monday, May 15th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have given a buy rating to the company. Imperva presently has a consensus rating of “Hold” and a consensus target price of $50.29.

Shares of Imperva (NYSE IMPV) opened at 50.85 on Thursday. The stock’s 50 day moving average is $49.16 and its 200 day moving average is $43.54. The firm’s market cap is $1.70 billion. Imperva has a 12 month low of $34.40 and a 12 month high of $57.24.

Imperva (NYSE:IMPV) last released its quarterly earnings data on Thursday, May 4th. The software maker reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.33. Imperva had a return on equity of 36.67% and a net margin of 31.92%. The company had revenue of $72.31 million during the quarter, compared to the consensus estimate of $68.16 million. During the same quarter in the prior year, the firm posted ($0.25) earnings per share. The firm’s revenue was up 21.0% compared to the same quarter last year. Analysts forecast that Imperva will post $0.45 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.watchlistnews.com/imperva-inc-impv-stock-rating-reaffirmed-by-stephens/1444569.html.

In other news, insider Amichai Shulman sold 3,089 shares of the firm’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $48.70, for a total transaction of $150,434.30. Following the completion of the sale, the insider now owns 100,151 shares of the company’s stock, valued at approximately $4,877,353.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CRO Michael D. Mooney sold 52,356 shares of the firm’s stock in a transaction that occurred on Wednesday, May 10th. The stock was sold at an average price of $47.51, for a total transaction of $2,487,433.56. Following the sale, the executive now directly owns 52,356 shares of the company’s stock, valued at approximately $2,487,433.56. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 60,302 shares of company stock valued at $2,875,861. Insiders own 2.20% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Imperva by 4.6% in the first quarter. Vanguard Group Inc. now owns 2,339,441 shares of the software maker’s stock valued at $96,033,000 after buying an additional 102,779 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Imperva by 2.2% in the first quarter. JPMorgan Chase & Co. now owns 1,627,998 shares of the software maker’s stock valued at $66,828,000 after buying an additional 34,653 shares during the period. Clearbridge Investments LLC increased its stake in shares of Imperva by 47.0% in the first quarter. Clearbridge Investments LLC now owns 1,262,507 shares of the software maker’s stock valued at $51,826,000 after buying an additional 403,809 shares during the period. Eagle Asset Management Inc. increased its stake in shares of Imperva by 4.1% in the first quarter. Eagle Asset Management Inc. now owns 1,087,223 shares of the software maker’s stock valued at $44,630,000 after buying an additional 43,278 shares during the period. Finally, North Run Capital LP increased its stake in shares of Imperva by 999.3% in the first quarter. North Run Capital LP now owns 750,000 shares of the software maker’s stock valued at $30,788,000 after buying an additional 681,772 shares during the period. 92.72% of the stock is owned by institutional investors.

About Imperva

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.

Analyst Recommendations for Imperva (NYSE:IMPV)

Receive News & Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.